PharmTech LCGC Sciex Webinar 11.10
|Articles|January 15, 2007

Thermo Fisher Buys SwissAnalytic

Thermo Fisher Scientific Inc. announced today it has acquired Basel, Switzerland-based SwissAnalytic Group AG, which owns Spectronex AG and Flux Instruments AG. Terms were not disclosed.

Thermo Fisher Scientific Inc. announced today it has acquired Basel, Switzerland-based SwissAnalytic Group AG, which owns Spectronex AG and Flux Instruments AG. Terms were not disclosed.

Spectronex is a supplier of mass spectrometry, chromatography and surface science instrumentation in Switzerland, Austria, Slovakia and the Czech Republic. Flux Instruments is a manufacturer of high-performance liquid chromatography (HPLC) pumps and software.

Thermo Fisher Scientific's current HPLC and liquid chromatography coupled mass spectroscopy (LCMS) business includes its Accela high-speed liquid chromatographIC system and advanced sample extraction and LC products gained when it acquired Massachusetts-based Cohesive Technologies Inc., a manufacturer of advanced sample extraction and liquid chromatography products, in December. (See: www.photonics.com/content/news/2006/December/15/85436.aspx)

"Flux Instruments is a strong complement to our expanding chromatography and life sciences mass spectrometry product lines," said Marijn E. Dekkers, president and CEO of Thermo Fisher Scientific. "In addition, Spectronex enables Thermo Fisher to strengthen our footprint in Europe with direct sales channels and support, enhancing our ability to work closely with important customers in this area."


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.